Axogen, Inc. (AXGN) — 8-K Filings

8-K Filings (15)

• Axogen Reports Q1 2026 Financial Results — Apr 28, 2026 Risk: low
  Axogen, Inc. filed an 8-K on April 28, 2026, reporting its financial results for the first quarter of 2026. The filing includes a press release and a financial
• Axogen Files 8-K: Director Changes & Financials — Dec 5, 2025 Risk: low
  Axogen, Inc. filed an 8-K on December 5, 2025, reporting on the departure of a director, the election of new directors, and compensatory arrangements. The filin
• Axogen Files 8-K: Regulation FD, Other Events, Exhibits — Dec 4, 2025 Risk: low
  Axogen, Inc. filed an 8-K on December 4, 2025, reporting events as of December 3, 2025. The filing includes information related to Regulation FD Disclosure, Oth
• Axogen's Avance® Nerve Graft Gets FDA Priority Review — Aug 25, 2025 Risk: medium
  Axogen, Inc. announced on August 22, 2025, that the U.S. Food and Drug Administration (FDA) has accepted for filing their supplemental Biologics License Applica
• Axogen Files 8-K on Shareholder Votes and Financials — Jun 20, 2025 Risk: low
  Axogen, Inc. filed an 8-K on June 18, 2025, reporting on a submission of matters to a vote of security holders and financial statements and exhibits. The filing
• Axogen, Inc. Files 8-K Report — Apr 7, 2025 Risk: low
  Axogen, Inc. filed an 8-K on April 7, 2025, reporting information under Regulation FD Disclosure and Financial Statements and Exhibits. The company, incorporate
• Axogen, Inc. Files 8-K Report — Mar 4, 2025 Risk: low
  Axogen, Inc. filed an 8-K on March 4, 2025, to report information under Regulation FD. The filing does not contain specific financial figures or material events
• Axogen, Inc. Files 8-K on Financials and Reg FD — Feb 25, 2025 Risk: low
  Axogen, Inc. filed an 8-K on February 25, 2025, reporting on its results of operations and financial condition, as well as a Regulation FD disclosure. The filin
• Axogen, Inc. Files 8-K on Financials — Jan 10, 2025 Risk: low
  Axogen, Inc. filed an 8-K on January 10, 2025, reporting on its results of operations and financial condition. The filing also included disclosures under Regula
• Axogen Inc. Files 8-K: Regulation FD & Exhibits — Sep 6, 2024 Risk: low
  Axogen, Inc. filed an 8-K on September 6, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain speci
• Axogen Appoints Dr. Steven J. Williams as New CMO — Aug 9, 2024 Risk: low
  Axogen, Inc. announced on August 8, 2024, the appointment of Dr. Steven J. Williams as Chief Medical Officer. Dr. Williams previously served as Chief Medical Of
• Axogen Appoints New CMO, Elects Directors — Jun 7, 2024 Risk: medium
  Axogen, Inc. announced on June 4, 2024, the appointment of Dr. Steven J. Shapiro as Chief Medical Officer and the election of Ms. Karen L. King and Mr. David M.
• Axogen Appoints New CMO, Director; Discloses Executive Pay — Mar 8, 2024 Risk: medium
  Axogen, Inc. announced on March 7, 2024, the appointment of Dr. Steven J. Hanley as Chief Medical Officer and the election of Ms. Karen L. King to its Board of
• Axogen Files 8-K for Regulation FD Disclosure on Jan 5, 2024 — Jan 8, 2024
  Axogen, Inc. filed an 8-K on January 5, 2024, to report a current event, specifically a Regulation FD Disclosure and Financial Statements and Exhibits. This fil
• Axogen 8-K: Financials & Officer Comp Updates on Jan 4, 2024 — Jan 4, 2024
  Axogen, Inc. filed an 8-K on January 4, 2024, reporting on its results of operations and financial condition, as well as changes in its executive compensation a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX